(Bloomberg) — Data on Sarepta Therapeutics Inc.’s experimental gene therapy for a rare type of muscular dystrophy showed that patients receiving a higher dose of the medicine saw greater benefits than those receiving a lower dose, delivering another early-stage win for the drug developer.Three patients with limb-girdle muscular dystrophy Type 2E who got the high dose of Sarepta’s SRP-9003 produced greater levels of the protein beta-sarcoglycan. While patients with the progressive and debilitating muscle-wasting disease normally make very little or none of the protein, the three children showed an average protein expression that was 62% of normal, topping 36% seen …read more
Source:: Yahoo Finance
